StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Meclofenamicsure

Meclofenamic Acid

HCID 4037
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
644-62-2
Standard-SMILES
Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
InChIKey
SBDNJUWAMKYJOX-UHFFFAOYSA-N
Summenformel
C14H11Cl2NO2
Durchschnittliche Molmasse
296,1 g/mol
Monoisotopische Masse
295,016684

Überblick

Meclofenamic acid is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug, an analgesic, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an antineoplastic agent, an anticonvulsant, an antirheumatic drug and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is an aminobenzoic acid, an organochlorine compound and a secondary amino compound. It is a conjugate acid of a meclofenamic acid(1-).

Namen und Bezeichner

Bevorzugter Name
Meclofenamic Acid
IUPAC
2-(2,6-dichloro-3-methylanilino)benzoic acid
Lokaler Name
Meclofenamicsure
Englischer Name
Meclofenamic acid
Summenformel
C14H11Cl2NO2
Molmasse
296.15

Namen und Synonyme

meclofenamic acidmeclofenamate644-62-2Arquel2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acidAcido meclofenamicoAcide meclofenamiqueINF 4668Acidum meclofenamicumN-(2,6-Dichloro-m-tolyl)anthranilic acidMeclomenCI-583
Weitere Namen anzeigen
MeclofenNSC 95309MeclorfenamicmeclofenamicaciMeclofemic acidMeclophenamic acidC14804500 MeclofenamiCacid
INF-4668N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acidN-(2,6-Dichloro-3-methylphenyl)anthranilic acidNSC-95309Arquel Tablets48I5LU4ZWDCL-583

Datenbank-Bezeichner

CAS
644-62-2
PubChem CID
4037
DTXSID
DTXSID0048559
ChEMBL
CHEMBL509
ChEBI

Eigenschaften

Berechnete Struktureigenschaften

XLogP
5,2
Polarare Oberfläche (TPSA)
49,3 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
3
Schwere Atome
19
Formalladung
0
Komplexität
327

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceutical

Pharmaceuticals -> Listed in ZINC15

LogP · 2 Einträge

5

5.9

Solubility3.66e-03 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

Pharmaceuticals

Animal DrugsFDA approved animal drugs -> Active ingredient
Melting Point · 2 Einträge

248-250

257 °C

Physical DescriptionSolid
Collision Cross Section155.91 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Meclofenamate

4.7

19.7

The recommended dose is 50 mg every 4 to 6 hours.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 200 mg/day, Lowest Therapeutic Dose (LTD): 2.5 mg/kg-day, and Screening Dose: 0.0008 mg/kg-day.

15-May-21

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingGreater than 99% bound to plasma proteins over a wide drug concentration range.
PharmacodynamicsMeclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.
Mechanism of Action · 1 Eintrag

The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.

Biological Half-LifeIn a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
Metabolism/Metabolites · 1 Eintrag

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Zugehörige Reaktionen

10
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 343884
HRID 343884als Edukt
Reaktionsgleichung von HRID 703206
HRID 703206als Edukt
Reaktionsgleichung von HRID 703216
HRID 703216als Edukt
Reaktionsgleichung von HRID 973955
HRID 973955als Edukt
Reaktionsgleichung von HRID 1088290
HRID 1088290als Edukt
Reaktionsgleichung von HRID 1195871
HRID 1195871als Edukt
Reaktionsgleichung von HRID 1461424
HRID 1461424als Edukt
Reaktionsgleichung von HRID 1461433
HRID 1461433als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEBI:6710
UNII
48I5LU4ZWD
EC Number
211-419-5
Nikkaji
J7.065C
Schmelzpunkt
257 · 257-259°C
Siedepunkt
399.4 · 399.4±42.0 °C(Predicted)
Dichte
1.3567 · 1.3567 (rough estimate)
Brechungsindex
1.607 · 1.6070 (estimate)
storage temp.
Refrigerator
Löslichkeit
Chloroform (Slightly), Methanol (Slightly, Heated)
Aggregatzustand
Solid
pka
4 · pKa 4.0 (Uncertain)
Farbe
Off-White to Light Orange
EPA chemische Informationen
2 · Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]- (644-62-2)

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 4 Einträge

Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.

Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.

9.1 to 43.2 L

Oral cl=206 mL/min

Cellular LocationsCytoplasm

Verwendung und Herstellung

Use ClassificationPharmaceuticals

Anwendungen

VerwendenMeclofenamic acid is used for the same conditions as flufenamic acid.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

4-Chlor-3-nitrotoluol2-Chlorbenzoesäure4-Ethylmorpholin2,6-Dichlor-m-toluidin
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoe (painful periods), osteoarthritis and rheumatoid arthritis.